113 related articles for article (PubMed ID: 14712936)
1. Generating data for databases--the peptide repertoire of HLA molecules.
Stevanović S; Lemmel C; Häntschel M; Eberle U
Novartis Found Symp; 2003; 254():143-55; discussion 155-64, 216-22, 250-2. PubMed ID: 14712936
[TBL] [Abstract][Full Text] [Related]
2. HLA-B27: a registry of constitutive peptide ligands.
Lopez de Castro JA; Alvarez I; Marcilla M; Paradela A; Ramos M; Sesma L; Vázquez M
Tissue Antigens; 2004 May; 63(5):424-45. PubMed ID: 15104674
[TBL] [Abstract][Full Text] [Related]
3. HLA-DP2: self peptide sequences and binding properties.
Chicz RM; Graziano DF; Trucco M; Strominger JL; Gorga JC
J Immunol; 1997 Nov; 159(10):4935-42. PubMed ID: 9366419
[TBL] [Abstract][Full Text] [Related]
4. Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype.
Hillen N; Mester G; Lemmel C; Weinzierl AO; Müller M; Wernet D; Hennenlotter J; Stenzl A; Rammensee HG; Stevanović S
Eur J Immunol; 2008 Nov; 38(11):2993-3003. PubMed ID: 18991276
[TBL] [Abstract][Full Text] [Related]
5. Extraordinary cross-reactivity of an autoimmune T-cell receptor recognizing specific peptides both on autologous and on allogeneic HLA class II molecules.
Hansen BE; Rasmussen AH; Jakobsen BK; Ryder LP; Svejgaard A
Tissue Antigens; 2007 Jul; 70(1):42-52. PubMed ID: 17559580
[TBL] [Abstract][Full Text] [Related]
6. Antigen processing is predictable: From genes to T cell epitopes.
Stevanovic S
Transpl Immunol; 2005 Aug; 14(3-4):171-4. PubMed ID: 15982559
[TBL] [Abstract][Full Text] [Related]
7. Purification and HPLC-MS analysis of a naturally processed HCMV-derived peptide isolated from the HEK-293T/HLA-E+/Ul40+ cell transfectants and presented at the cell surface in the context of HLA-E.
Millo E; Pietra G; Armirotti A; Vacca P; Mingari MC; Moretta L; Damonte G
J Immunol Methods; 2007 Apr; 322(1-2):128-36. PubMed ID: 17331531
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive analysis of constitutive naturally processed and presented HLA-C*04:01 (Cw4)-specific peptides.
Schittenhelm RB; Dudek NL; Croft NP; Ramarathinam SH; Purcell AW
Tissue Antigens; 2014 Mar; 83(3):174-9. PubMed ID: 24397554
[TBL] [Abstract][Full Text] [Related]
9. Structural prediction of peptides binding to MHC class I molecules.
Bui HH; Schiewe AJ; von Grafenstein H; Haworth IS
Proteins; 2006 Apr; 63(1):43-52. PubMed ID: 16447245
[TBL] [Abstract][Full Text] [Related]
10. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.
Han JF; Zhao TT; Liu HL; Lin ZH; Wang HM; Ruan ZH; Zou LY; Wu YZ
Cancer Immunol Immunother; 2006 Dec; 55(12):1575-83. PubMed ID: 16534571
[TBL] [Abstract][Full Text] [Related]
11. Determination of the peptide binding motif and high-affinity ligands for HLA-DQ4 using synthetic peptide libraries.
Volz T; Schwarz G; Fleckenstein B; Schepp CP; Haug M; Roth J; Wiesmüller KH; Dannecker GE
Hum Immunol; 2004 Jun; 65(6):594-601. PubMed ID: 15219379
[TBL] [Abstract][Full Text] [Related]
12. Identification of class II HLA-DRB1*03-bound measles virus peptides by 2D-liquid chromatography tandem mass spectrometry.
Johnson KL; Ovsyannikova IG; Poland GA; Muddiman DC
J Proteome Res; 2005; 4(6):2243-9. PubMed ID: 16335972
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of two chemically modified peptide epitopes for the class I MHC protein HLA-B*2705.
Jones MA; Hislop AD; Snaith JS
Org Biomol Chem; 2006 Oct; 4(20):3769-77. PubMed ID: 17024283
[TBL] [Abstract][Full Text] [Related]
14. Allele-specific peptide presentation of human leukocyte antigens: implications for tumor immunotherapy.
Elsner HA; Eiz-Vesper B; Blasczyk R; Bade-Döding C
Anticancer Res; 2007; 27(4A):2075-7. PubMed ID: 17649824
[TBL] [Abstract][Full Text] [Related]
15. HLA-peptide binding prediction using structural and modeling principles.
Kangueane P; Sakharkar MK
Methods Mol Biol; 2007; 409():293-9. PubMed ID: 18450009
[TBL] [Abstract][Full Text] [Related]
16. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses.
Hirano N; Butler MO; Xia Z; Berezovskaya A; Murray AP; Ansén S; Nadler LM
Clin Cancer Res; 2006 May; 12(10):2967-75. PubMed ID: 16707591
[TBL] [Abstract][Full Text] [Related]
17. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5.
Sensi M; Pietra G; Molla A; Nicolini G; Vegetti C; Bersani I; Millo E; Weiss E; Moretta L; Mingari MC; Anichini A
Int Immunol; 2009 Mar; 21(3):257-68. PubMed ID: 19181932
[TBL] [Abstract][Full Text] [Related]
18. Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide-HLA Interactions.
Bassani-Sternberg M; Gfeller D
J Immunol; 2016 Sep; 197(6):2492-9. PubMed ID: 27511729
[TBL] [Abstract][Full Text] [Related]
19. The peptide length specificity of some HLA class I alleles is very broad and includes peptides of up to 25 amino acids in length.
Bell MJ; Burrows JM; Brennan R; Miles JJ; Tellam J; McCluskey J; Rossjohn J; Khanna R; Burrows SR
Mol Immunol; 2009 May; 46(8-9):1911-7. PubMed ID: 19157553
[TBL] [Abstract][Full Text] [Related]
20. Class II HLA-peptide binding prediction using structural principles.
Mohanapriya A; Lulu S; Kayathri R; Kangueane P
Hum Immunol; 2009 Mar; 70(3):159-69. PubMed ID: 19187794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
